Cargando…
Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
BACKGROUND: Patients with atrial fibrillation (AF) and hypertension are at high risk for stroke. Previous studies have shown elevated risk of stroke in patients with AF who have a history of hypertension (regardless of blood pressure [BP] control) and in patients with elevated BP. We assessed the as...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845276/ https://www.ncbi.nlm.nih.gov/pubmed/26627878 http://dx.doi.org/10.1161/JAHA.115.002015 |
_version_ | 1782428909988478976 |
---|---|
author | Rao, Meena P. Halvorsen, Sigrun Wojdyla, Daniel Thomas, Laine Alexander, John H. Hylek, Elaine M. Hanna, Michael Bahit, M. Cecilia Lopes, Renato D. De Caterina, Raffaele Erol, Cetin Goto, Shinya Lanas, Fernando Lewis, Basil S. Husted, Steen Gersh, Bernard J. Wallentin, Lars Granger, Christopher B. |
author_facet | Rao, Meena P. Halvorsen, Sigrun Wojdyla, Daniel Thomas, Laine Alexander, John H. Hylek, Elaine M. Hanna, Michael Bahit, M. Cecilia Lopes, Renato D. De Caterina, Raffaele Erol, Cetin Goto, Shinya Lanas, Fernando Lewis, Basil S. Husted, Steen Gersh, Bernard J. Wallentin, Lars Granger, Christopher B. |
author_sort | Rao, Meena P. |
collection | PubMed |
description | BACKGROUND: Patients with atrial fibrillation (AF) and hypertension are at high risk for stroke. Previous studies have shown elevated risk of stroke in patients with AF who have a history of hypertension (regardless of blood pressure [BP] control) and in patients with elevated BP. We assessed the association of hypertension and BP control on clinical outcomes. METHODS AND RESULTS: In ARISTOTLE (n=18 201), BP was evaluated as history of hypertension requiring treatment and elevated BP (systolic ≥140 and/or diastolic ≥90 mm Hg) at study entry and any point during the trial. Hazard ratios (HRs) were derived from Cox proportional hazards models including BP as a time‐dependent covariate. A total of 15 916 (87.5%) patients had a history of hypertension requiring treatment. In patients with elevated BP measurement at any point during the trial, the rate of stroke or systemic embolism was significantly higher (HR, 1.53; 95% confidence interval [CI], 1.25–1.86), as was hemorrhagic stroke (HR 1.85; 95% CI, 1.26–2.72) and ischemic stroke (HR, 1.50; 95% CI, 1.18–1.90). Rates of major bleeding were lower in patients with a history of hypertension (HR, 0.80; 95% CI, 0.66–0.98) and nonsignificantly lower in patients with elevated BP at study entry (HR, 0.89; 95% CI, 0.77–1.03). The benefit of apixaban versus warfarin on preventing stroke or systemic embolism was consistent among patients with and without a history of hypertension (P interaction=0.27), BP control at baseline (P interaction=0.43), and BP control during the trial (P interaction=0.97). CONCLUSIONS: High BP measurement at any point during the trial was independently associated with a substantially higher risk of stroke or systemic embolism. These results strongly support efforts to treat elevated BP as an important strategy to optimally lower risk of stroke in patients with AF. CLINICAL TRIAL REGISTRATION: URL: https://ClinicalTrials.gov/. Unique identifier: NCT00412984. |
format | Online Article Text |
id | pubmed-4845276 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-48452762016-04-27 Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial Rao, Meena P. Halvorsen, Sigrun Wojdyla, Daniel Thomas, Laine Alexander, John H. Hylek, Elaine M. Hanna, Michael Bahit, M. Cecilia Lopes, Renato D. De Caterina, Raffaele Erol, Cetin Goto, Shinya Lanas, Fernando Lewis, Basil S. Husted, Steen Gersh, Bernard J. Wallentin, Lars Granger, Christopher B. J Am Heart Assoc Original Research BACKGROUND: Patients with atrial fibrillation (AF) and hypertension are at high risk for stroke. Previous studies have shown elevated risk of stroke in patients with AF who have a history of hypertension (regardless of blood pressure [BP] control) and in patients with elevated BP. We assessed the association of hypertension and BP control on clinical outcomes. METHODS AND RESULTS: In ARISTOTLE (n=18 201), BP was evaluated as history of hypertension requiring treatment and elevated BP (systolic ≥140 and/or diastolic ≥90 mm Hg) at study entry and any point during the trial. Hazard ratios (HRs) were derived from Cox proportional hazards models including BP as a time‐dependent covariate. A total of 15 916 (87.5%) patients had a history of hypertension requiring treatment. In patients with elevated BP measurement at any point during the trial, the rate of stroke or systemic embolism was significantly higher (HR, 1.53; 95% confidence interval [CI], 1.25–1.86), as was hemorrhagic stroke (HR 1.85; 95% CI, 1.26–2.72) and ischemic stroke (HR, 1.50; 95% CI, 1.18–1.90). Rates of major bleeding were lower in patients with a history of hypertension (HR, 0.80; 95% CI, 0.66–0.98) and nonsignificantly lower in patients with elevated BP at study entry (HR, 0.89; 95% CI, 0.77–1.03). The benefit of apixaban versus warfarin on preventing stroke or systemic embolism was consistent among patients with and without a history of hypertension (P interaction=0.27), BP control at baseline (P interaction=0.43), and BP control during the trial (P interaction=0.97). CONCLUSIONS: High BP measurement at any point during the trial was independently associated with a substantially higher risk of stroke or systemic embolism. These results strongly support efforts to treat elevated BP as an important strategy to optimally lower risk of stroke in patients with AF. CLINICAL TRIAL REGISTRATION: URL: https://ClinicalTrials.gov/. Unique identifier: NCT00412984. John Wiley and Sons Inc. 2015-12-01 /pmc/articles/PMC4845276/ /pubmed/26627878 http://dx.doi.org/10.1161/JAHA.115.002015 Text en © 2015 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Research Rao, Meena P. Halvorsen, Sigrun Wojdyla, Daniel Thomas, Laine Alexander, John H. Hylek, Elaine M. Hanna, Michael Bahit, M. Cecilia Lopes, Renato D. De Caterina, Raffaele Erol, Cetin Goto, Shinya Lanas, Fernando Lewis, Basil S. Husted, Steen Gersh, Bernard J. Wallentin, Lars Granger, Christopher B. Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial |
title | Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial |
title_full | Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial |
title_fullStr | Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial |
title_full_unstemmed | Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial |
title_short | Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial |
title_sort | blood pressure control and risk of stroke or systemic embolism in patients with atrial fibrillation: results from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (aristotle) trial |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845276/ https://www.ncbi.nlm.nih.gov/pubmed/26627878 http://dx.doi.org/10.1161/JAHA.115.002015 |
work_keys_str_mv | AT raomeenap bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial AT halvorsensigrun bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial AT wojdyladaniel bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial AT thomaslaine bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial AT alexanderjohnh bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial AT hylekelainem bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial AT hannamichael bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial AT bahitmcecilia bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial AT lopesrenatod bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial AT decaterinaraffaele bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial AT erolcetin bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial AT gotoshinya bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial AT lanasfernando bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial AT lewisbasils bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial AT hustedsteen bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial AT gershbernardj bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial AT wallentinlars bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial AT grangerchristopherb bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial AT bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial |